ProQR Therapeutics Price Target Maintained at $3.00 by Chardan Capital
Chardan Capital maintained its price target of $3.00 per share for ProQR Therapeutics.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.